No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
August 2018
Apexigen raises a $73,000,000 series B round from SV Tech Ventures, Decheng Capital, 3E Bioventures Capital and VI Ventures.
August 6, 2013
Apexigen raises a $20,000,000 series A round from Amkey Ventures and Sycamore Ventures.
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
73,000,000
August 2018
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Apexigen, Inc.
January 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive...
BioSpace
November 9, 2020
BioSpace
Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced two upcoming poster presentations at the 35th Society for Immunotherapy of Cancer Annual Meeting, to be held November 9-14, 2020.
Apexigen, Inc.
November 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...
BioSpace
June 4, 2020
BioSpace
Apexigen, Inc. announced the appointment of Gordon Ringold, Ph.D., to its Board of Directors.
Is a
Company attributes
Location
Legal name
Apexigen Inc.
Investors
Total funding amount (USD)
286,000,000
Latest funding round date
March 24, 2020